Randomized phase II trial of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus capecitabine in patients with advanced breast cancer.
Clinical Breast Cancer(2014)
摘要
This study assessed the efficacy and safety of dinaciclib, a cyclin-dependent kinase inhibitor, compared with capecitabine in patients with previously treated advanced breast cancer. Thirty women were randomized in this multicenter, open-label, phase II trial. Dinaciclib demonstrated similar but not superior antitumor activity to capecitabine. Future studies may consider dinaciclib for select patients and in combination with other agents.
更多查看译文
关键词
Efficacy,Monotherapy,Safety,Small-molecule inhibitor,Solid tumors
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要